Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc (NQ: COSM )

1.040 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 864,752
Open 1.040
Bid (Size) 0.9110 (9)
Ask (Size) 0.9199 (1)
Prev. Close 1.040
Today's Range 1.040 - 1.040
52wk Range 0.4677 - 3.418
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Cosmos Health Stock Is Trading Higher Friday
On Thursday afternoon, the global healthcare company announced it had signed an exclusive distribution agreement with Pharmalink for 130,000 units of its Sky Premium Life products in the United Arab... 
Via Benzinga
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning. 
Via InvestorPlace

Performance

YTD
-24.09%
-24.09%
1 Month
+50.79%
+50.79%
3 Month
+48.57%
+48.57%
6 Month
-24.09%
-24.09%
1 Year
-66.67%
-66.67%

More News

Read More
Why Is Nexalin Technology (NXL) Stock Down 35% Today?
Via InvestorPlace
Why Is Cosmos Health (COSM) Stock Up 65% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units
Via ACCESSWIRE
Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
Via ACCESSWIRE
Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q
Via ACCESSWIRE
Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand
Via ACCESSWIRE
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Healthcare Stocks
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
Via ACCESSWIRE
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
Via ACCESSWIRE
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
Via ACCESSWIRE
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
Via ACCESSWIRE
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
Via ACCESSWIRE
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
Via ACCESSWIRE
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
Via ACCESSWIRE
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
Via ACCESSWIRE
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.